Epidural abscess medical therapy

Jump to navigation Jump to search

Epidural abscess Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Epidural abscess from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Epidural abscess medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Epidural abscess medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Epidural abscess medical therapy

CDC on Epidural abscess medical therapy

Epidural abscess medical therapy in the news

Blogs on Epidural abscess medical therapy

Directions to Hospitals Treating Epidural abscess

Risk calculators and risk factors for Epidural abscess medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

An epidural abscess is a rare suppurative infection of the central nervous system, a collection of pus localised in the epidural space, lying outside the dura mater, which accounts for less than 2% of focal CNS infections. [1] It may occur in two different places: intracranially or in the spinal canal. Due to the fact that the initial symptoms and clinical characteristics are not always identical and are similar to other diseases, along with the fact that they are both rare conditions, the final diagnosis might be delayed in time. This late diagnosis comes at great cost to the patient, since it is usually accompanied by a bad prognosis and severe complications, with a potential fatal outcome. According to the location of the collection, the abscess may have different origins, different organisms involved, symptoms, evolutions, complications and therapeutical techniques. [2] The treatment of epidural abscess focuses in two main aspects: reduction of the inflammatory mass and eradication of the responsible organism. These goals can be reached through a combination of medical and surgical approaches. An early surgical decompression and drainage, along with an aggressive antibiotic treatment is the ideal procedure to increase the chances of a better outcome.

Medical Therapy

Several studies have reached the conclusion that the best approach to therapy of epidural abscess, either intracranial or spinal, is a combination of surgical drainage along with prolonged systemic antibiotics (6-12 weeks, IV followed by PO). [3] Due to the importance of preoperative neurologic status, along with the unpredictable progression of neurologic impairment, for the neurological outcome of the patient, decompressive laminectomy and debridement of infected tissues, in the case of SEA, and burr hole placement or craniotomy, in the case of IEA, should take place as early as possible. [4][5] However, in certain clinical scenarios, medical therapy may be the only treatment indicated for that particular case, these include:

  • decompressive laminectomy declined by the patient
  • high operative risk
  • paralysis unlikely reversible, due to being present for more than 24 to 36 hours. Sometimes, in these situations emergency laminectomy is still performed, not to restore the lost function, but to treat the abscess and prevent a sepsis episode
  • panspinal infection, therefore the laminectomy would be impracticable. In this case, the physician might consider a limited laminectomy or laminotomy with catheter insertion at the top and bottom of the spinal canal, for drainage and irrigation.

There are several reported cases in which patients recovered from epidural abscess, without surgical treatment, following simple diagnostic aspiration with antibiotic therapy. In these patients however, there was no neurologic deficit related to the abscess or it was simply accompanied by minor weakness at initial presentation. [6] Besides the antibiotic therapy, this conservative approach also includes:

  • close neurologic monitoring strategy, defined before treatment initiation
  • follow-up MRI to evaluate the status of the abscess and confirm its resolution
  • immediate surgery, in case of neurologic deterioration.

The indication for a specific antibiotic should be given by the results of blood cultures or a CT-guided aspiration of the abscess. However, until blood culture results are obtained, the patient should be on empirical antibiotic therapy. The efficacy of the antibiotic treatment, as well as its duration, may be determined by monitoring the evolution of the ESR, CRP, pain and function, along with resolution of radiographic changes. [3]

Intracranial Epidural Abscess

The empiric antibiotic therapy for this type of abscess is similar to the one used for subdural empyema and should be continued for 3 to 6 weeks after surgery, or longer in case of osteomyelitis. [7] This should cover: [4]

This regimen must include: [8][3]

Spinal Epidural Abscess

Initial antibiotic therapy for this type of abscess should target staphylococci and aerobic gram negative bacilli, particularly in patients with history of IV drug use or spinal procedures. The treatment should last for a period of 4 to 6 weeks, or longer, up to 8 weeks, in case there is contiguous osteomyelitis. [9] Therefore, the antibiotic regimens for the unknown organism of intracranial epidural abscess may also be applied to the spinal epidural abscess.

Antibiotic Therapy

▸ Click on the following categories to expand treatment regimens.

Age and Predisposing Factors

  ▸  Infants < 1 month

  ▸  Infants 1-3 months

  ▸  > 3 months Immunocompetent Children; Adults < 55 years

  ▸  Adults > 55 years; Alcoholics; Debilitating Illness

  ▸  Specific Situations

Infants < 1 month
Preferred Regimen
Ampicillin 200 mg/kg/day IV, q4h
PLUS
Cefotaxime 200 mg/kg/day IV, q6h
Infants 1-3 months
Preferred Regimen
Ampicillin 200 mg/kg/day IV, q4h
PLUS
Cefotaxime 200 mg/kg/day IV, q6h
OR
Ceftriaxone 100 mg/kg/day IV, q12h
> 3 months Immunocompetent Children; Adults < 55 years
Preferred Regimen
Vancomycin Child: 60 mg/kg/day IV, q6h; Adult: 2 g/day IV, q12h
PLUS
Cefotaxime Child: 200 mg/kg/day IV, q6h; Adult: 12 g/day IV, q4h
OR
Ceftriaxone Child: 100 mg/kg/day IV, q12h; Adult: 4 g/day IV, q12h
OR
Cefepime Child: 150 mg/kg/day IV, q8h; Adult: 6 g/day IV, q8h
Might be added Metronidazole Child: 30 mg/kg/day, q6h; Adult: 1500-2000 mg/day, q6h
Adults > 55 years; Alcoholics; Debilitating Illness
Preferred Regimen
Ampicillin Child: 200 mg/kg/day IV, q4h; Adult: 12 g/day IV, q4h
PLUS
Vancomycin Child: 60 mg/kg/day IV, q6h; Adult: 2 g/day IV, q12h
PLUS
Cefotaxime Child: 200 mg/kg/day IV, q6h; Adult: 12 g/day IV, q4h
OR
Ceftriaxone Child: 100 mg/kg/day IV, q12h; Adult: 4 g/day IV, q12h
OR
Cefepime Child: 150 mg/kg/day IV, q8h; Adult: 6 g/day IV, q8h
Specific Situations
Preferred Regimen
Ampicillin Child: 200 mg/kg/day IV, q4h; Adult: 12 g/day IV, q4h
PLUS
Vancomycin Child: 60 mg/kg/day IV, q6h; Adult: 2 g/day IV, q12h
PLUS
Ceftazidime Child: 150 mg/kg/day IV, q8h; Adult: 6 g/day IV, q8h
OR
Meropenem Child: 120 mg/kg/day IV, q8h; Adult: 3 g/day IV, q8h
Hospital Acquired Meningitis; Posttraumatic Meningitis; Postneurosurgery   Meningitis; Neutropenia; Impaired Cell-mediated Immunity

When the responsible organism has been isolated and identified in cultures, the therapy should be re-directed to this agent. [11]

▸ Click on the following categories to expand treatment regimens.

Pathogen-Based Therapy

  ▸  Neisseria meningitidis

  ▸  Streptococcus pneumoniae

  ▸  Gram negative bacilli

  ▸  Pseudomonas aeruginosa

  ▸  Staphylococci

  ▸  Listeria monocytogenes

  ▸  Haemophilus influenzae

  ▸  Streptococcus agalactiae

  ▸  Bacteroides fragilis

  ▸  Fusobacterium spp.

Neisseria meningitidis
Penicillin-sensitive
Penicillin G 20-24 million U/day IV, q4h
OR
Ampicillin 12 g/day IV, q4h
Penicillin-resistant
Ceftriaxone 4 g/day IV, q12h
OR
Cefotaxime 12 g/day IV, q4h
Streptococcus pneumoniae
Penicillin-sensitive
Penicillin G 20-24 million U/day IV, q4h
Relatively Penicillin-resistant
Ceftriaxone 4 g/day IV, q12h
OR
Cefotaxime 12 g/day IV, q4h
Penicillin-resistant
Vancomycin 2 g/day IV, q6h
PLUS
Ceftriaxone 4 g/day IV, q12h
OR
Cefotaxime 12 g/day IV, q4h
WITH/WITHOUT
Intraventricular Vancomycin 20 mg/day
Gram negative bacilli
Preferred Regimen
Ceftriaxone 4 g/day IV, q12H
OR
Cefotaxime 12 g/day IV, q4h
Pseudomonas aeruginosa
Preferred Regimen
Ceftazidime 6 g/day IV, q8h
Staphylococci
Methicillin-sensitive
Nafcillin 9-12 g/day IV, q4h
Methicillin-resistant
Vancomycin 2 g/day IV, q6h
Listeria monocytogenes
Preferred Regimen
Ampicillin 12 g/day IV, q4h
Haemophilus influenzae
Preferred Regimen
Ceftriaxone 4 g/day IV, q12h
OR
Cefotaxime 12 g/day IV, q4h
Streptococcus agalactiae
Preferred Regimen
Ampicillin 12 g/day IV, q4h
OR
Penicillin G 20-24 million U/day IV, q4h
Bacteroides fragilis
Preferred Regimen
Metronidazole 2000 mg/day IV, q6h
Fusobacterium spp.
Preferred Regimen
Metronidazole 2000 mg/day IV, q6h

Epidural Abscess Drug Summary

Nafcillin and Oxacillin

  • Group of narrow spectrum antibiotics, of the penicillin class, both penicillinase-resistant. Their mechanism of action is based on binding transpeptidases, thereby blocking the cross-linkage of peptidoglycan. They are also involved in the activation of autolytic enzymes.

Vancomycin

Cephalosporin

Metronidazole

Carbapenem

References

  1. Longo, Dan L. (Dan Louis) (2012). Harrison's principles of internal medici. New York: McGraw-Hill. ISBN 978-0-07-174889-6.
  2. Danner, R. L.; Hartman, B. J. (1987). "Update of Spinal Epidural Abscess: 35 Cases and Review of the Literature". Clinical Infectious Diseases. 9 (2): 265–274. doi:10.1093/clinids/9.2.265. ISSN 1058-4838.
  3. 3.0 3.1 3.2 Grewal, S. (2006). "Epidural abscesses". British Journal of Anaesthesia. 96 (3): 292–302. doi:10.1093/bja/ael006. ISSN 0007-0912.
  4. 4.0 4.1 Darouiche, Rabih O. (2006). "Spinal Epidural Abscess". New England Journal of Medicine. 355 (19): 2012–2020. doi:10.1056/NEJMra055111. ISSN 0028-4793.
  5. Darouiche RO, Hamill RJ, Greenberg SB, Weathers SW, Musher DM (1992). "Bacterial spinal epidural abscess. Review of 43 cases and literature survey". Medicine (Baltimore). 71 (6): 369–85. PMID 1359381.
  6. Wheeler D, Keiser P, Rigamonti D, Keay S (1992). "Medical management of spinal epidural abscesses: case report and review". Clin Infect Dis. 15 (1): 22–7. PMID 1617070.
  7. Mandell, Gerald L.; Bennett, John E. (John Eugene); Dolin, Raphael. (2010). Mandell, Douglas, and Bennett's principles and practice of infectious disease. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN 0-443-06839-9.
  8. Longo, Dan L. (Dan Louis) (2012). Harrison's principles of internal medici. New York: McGraw-Hill. ISBN 978-0-07-174889-6.
  9. Mandell, Gerald L.; Bennett, John E. (John Eugene); Dolin, Raphael. (2010). Mandell, Douglas, and Bennett's principles and practice of infectious disease. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN 0-443-06839-9.
  10. Longo, Dan L. (Dan Louis) (2012). Harrison's principles of internal medici. New York: McGraw-Hill. ISBN 978-0-07-174889-6.
  11. Longo, Dan L. (Dan Louis) (2012). Harrison's principles of internal medici. New York: McGraw-Hill. ISBN 978-0-07-174889-6.
  12. Longo, Dan L. (Dan Louis) (2012). Harrison's principles of internal medici. New York: McGraw-Hill. ISBN 978-0-07-174889-6.
  13. 13.0 13.1 13.2 Greenlee JE (2003). "Subdural Empyema". Curr Treat Options Neurol. 5 (1): 13–22. PMID 12521560.